Undervalued Biotechnology Stocks on TSX July 2024

July 21, 2024

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

TSX Venture Exchange

The TSX Venture Exchange is a stock exchange headquartered in Calgary, Alberta, Canada. It is an exchange for the securities of early-stage businesses.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
QPT Quest PharmaTech 0.03 0.07 176.96 7156 4 0.00 0.0
HEM Hemostemix 0.04 0.09 93.86 84745 4 0.00 0.0
SBM Sirona Biochem 0.04 0.07 51.79 28256 11 0.00 0.0
MRVL Marvel Biosciences 0.12 0.18 51.38 19028 5 0.00 0.0
CYTO Cytophage Technologies 0.30 0.45 50.24 26128 15 0.00 0.0
XRTX XORTX Therapeutics 2.34 3.20 36.85 4524 6 0.00 0.0
GSD Devonian Health Gr 0.13 0.18 36.16 9886 24 0.00 0.0
VXL Vaxil Bio 0.01 0.01 32.32 - 1 0.00 0.0
NRX NurExone Biologic 0.72 0.76 5.66 89619 41 0.00 0.0
COV Covalon Technologies 2.07 2.18 5.23 9215 51 0.00 0.0
All data provided as at market close July 18, 2024.

Company Details

Quest PharmaTech

QPT:TSX-V

Close Price

0.03

Our Valuation

0.07

% Difference

176.96

Market Cap ($M)

4

P/E Ratio

0.0

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

Access the stockcalc valuation


Hemostemix

HEM:TSX-V

Close Price

0.04

Our Valuation

0.09

% Difference

93.86

Market Cap ($M)

4

P/E Ratio

0.0

Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.

Access the stockcalc valuation


Sirona Biochem

SBM:TSX-V

Close Price

0.04

Our Valuation

0.07

% Difference

51.79

Market Cap ($M)

11

P/E Ratio

0.0

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.

Access the stockcalc valuation


Marvel Biosciences

MRVL:TSX-V

Close Price

0.12

Our Valuation

0.18

% Difference

51.38

Market Cap ($M)

5

P/E Ratio

0.0

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Cytophage Technologies

CYTO:TSX-V

Close Price

0.30

Our Valuation

0.45

% Difference

50.24

Market Cap ($M)

15

P/E Ratio

0.0

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants.

Access the stockcalc valuation


XORTX Therapeutics

XRTX:TSX-V

Close Price

2.34

Our Valuation

3.20

% Difference

36.85

Market Cap ($M)

6

P/E Ratio

0.0

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.

Access the stockcalc valuation


Devonian Health Gr

GSD:TSX-V

Close Price

0.13

Our Valuation

0.18

% Difference

36.16

Market Cap ($M)

24

P/E Ratio

0.0

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It is intended to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof.

Access the stockcalc valuation


Vaxil Bio

VXL:TSX-V

Close Price

0.01

Our Valuation

0.01

% Difference

32.32

Market Cap ($M)

1

P/E Ratio

0.0

Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.

Access the stockcalc valuation


NurExone Biologic

NRX:TSX-V

Close Price

0.72

Our Valuation

0.76

% Difference

5.66

Market Cap ($M)

41

P/E Ratio

0.0

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI).

Access the stockcalc valuation


Covalon Technologies

COV:TSX-V

Close Price

2.07

Our Valuation

2.18

% Difference

5.23

Market Cap ($M)

51

P/E Ratio

0.0

Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Quest PharmaTech and Hemostemix are the most undervalued Biotechnology stocks on the TSX. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-july-2024
Quest PharmaTech $QPT and Hemostemix $HEM are the most undervalued Biotechnology stocks on the #TSX. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-july-2024
Quest PharmaTech and Hemostemix are the most undervalued Biotechnology stocks on the TSX. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-july-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.